FreeStyle Libre 2: Now available in most pharmacies¹ and covered by Medicare.²

That’s it. That's the story.

You want more? Oh, we have more.

For people living with diabetes — including Medicare patients who meet eligibility criteria — the FreeStyle Libre 2 integrated continuous glucose monitoring system, recently cleared by the U.S. Food and Drug Administration, offers a lot more above and beyond its unsurpassed 14-day accuracy.³

• It’s the only iCGM that measures glucose every minute — five times more often than other CGMs^4,5 — all while meeting the highest level of accuracy standards.⁶
• Available for kids 4 and up. That’s right. We’re broadening the impact of this revolutionary technology. That’s more. Much more.
• At 14 days, it’s the longest-lasting iCGM available, nearly 40 percent longer.⁷ And with its built-in shutoff at 14 days, you can trust in its reliability.
• Alarms that are optional, customizable and real-time, alerting you within a minute if you’re too high or too low without having to scan.⁸

That’s more. But that’s not all. In some ways, less is more:

• Compared to other CGMs, the FreeStyle Libre 2 system will cost 70% less. More features, excellent accuracy, all at significantly lower cost.⁹
• Our latest technology reduces false alarms for kids by a third compared with the other iCGM available¹⁰ in the U.S. Fewer false alarms.

For many of the 34 million Americans living with diabetes, Medicare reimbursement is a welcome development.¹¹

"By securing reimbursement, we are making sure our latest life-changing technology can get to everyone who needs it, whether they're children, adults or seniors eligible for Medicare," said Jared Watkin, senior vice president, Diabetes Care, Abbott.

How life-changing is the FreeStyle Libre system?

In data presented¹² at the American Diabetes Association (ADA) 80th Scientific Sessions, the FreeStyle Libre system was found to offer Significant reduction in hemoglobin A1c (HbA1c) among people with type 2 diabetes for both long-acting insulin and non-insulin users, results that are similar to those typically seen when adding insulin to treatment regimens as well as fewer diabetes-related complications and hospitalizations among people with type 2 diabetes who were not on intensive insulin therapy.

Want to know even more about FreeStye Libre 2? There’s more here.

¹Participating pharmacies are subject to change without notice. Product availability may vary by retailer.
²Patients must meet Medicare eligibility coverage criteria. Local Coverage Determination: Glucose Monitors (L33822), January 2020.
³FreeStyle Libre 2 User Guide.
⁴Data on file. Abbott Diabetes Care.
⁵Dexcom G6 CGM User Guide.
⁶Based on FDA iCGM special controls.
⁷Based on comparison to Dexcom G6.
⁸Notifications will only be received when alarms are turned on and the sensor is within 20 feet of the reading device.
⁹Based on a comparison of list prices of the FreeStyle Libre 14 day system versus competitors' CGM systems. FreeStyle Libre 2 system will be list priced the same rate as FreeStyle Libre 14 day system. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
¹⁰FreeStyle Libre 2 system user manual. Dexcom G6 CGM User Guide. Based on low glucose alarms set at 70 mg/dl. for pediatrics.
¹¹American Diabetes Association: Statistics About Diabetes.
¹²Miller, Brandner et al. HbA1c Reduction After Initiation of the FreeStyle Libre System in Type 2 Diabetes Patients on Long-Acting Insulin or Non-Insulin Therapy. Miller et al. FreeStyle Libre System Use Associated with Reduction in Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes Without Bolus Insulin. Wright et al. HbA1c Reduction Associated with a FreeStyle Libre System in People with Type 2 Diabetes Not on Bolus Insulin Therapy.

The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.

This story was originally published on July 31, 2020, and updated on Sept. 1, 2020.